Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24071271 | 1.00 | LMNA (0.32) | LMNAALDH1A1HSD17B10NR1I2CYP1A2 | |
| SCHEMBL30952238 | 0.97 | NR1I2 (0.33) | LMNAALDH1A1HSD17B10NR1I2CYP1A2 | |
| SCHEMBL28380158 | 0.85 | FOLH1 (0.36) | LMNAALDH1A1HSD17B10NR1I2CYP1A2 | |
| SCHEMBL4941271 | 0.84 | LMNA (0.35) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL11650649 | 0.82 | LMNA (0.46) | LMNAALDH1A1HSD17B10NR1I2CYP1A2 | |
| SCHEMBL11650412 | 0.82 | LMNA (0.46) | LMNAALDH1A1HSD17B10NR1I2CYP1A2 | |
| SCHEMBL2568250 | 0.81 | FOLH1 (0.35) | — | |
| SCHEMBL29180273 | 0.80 | FOLH1 (0.36) | LMNAALDH1A1HSD17B10NR1I2CYP1A2 | |
| SCHEMBL15135655 | 0.80 | FOLH1 (0.36) | LMNAALDH1A1HSD17B10NR1I2CYP1A2 | |
| SCHEMBL11653036 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346744-A1 | SULFUR-CONTAINING COMPOUND USEFUL FOR TREATING OR PREVENTING PRESBYOPIA | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230346744-A1 | SULFUR-CONTAINING COMPOUND USEFUL FOR TREATING OR PREVENTING PRESBYOPIA | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2023-11-02 | — | — | US | disclosed |
| CN-115515570-A | Sulfur-containing compounds useful for the treatment or prevention of presbyopia | 参天制药株式会社 | 2022-12-23 | — | — | CN | disclosed |
| WO-2021241582-A1 | SULFUR-CONTAINING COMPOUND USEFUL FOR TREATING OR PREVENTING PRESBYOPIA | 参天製薬株式会社 | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346744-A1 | SULFUR-CONTAINING COMPOUND USEFUL FOR TREATING OR PREVENTING PRESBYOPIA | CBS, PSEN1, PSEN2 | LMNA 2969/4885ALDH1A1 2707/4885HSD17B10 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.